Mitochondrial Disorders in Malignant Hyperthermia

  • Geneviève Kozak-Ribbens
Conference paper


Some muscle disorders are known to be associated with malignant hyperthermia (MH), including King-Denborough syndrome and central-core disease (CCD), and occasionally Duchenne muscular dystrophy and myotonias. Among them, mitochondrial myopathies (MM) have been occasionally reported [1,2]. In a recent publication by Harriman concerning 1400 patients investigated by the Leeds MH unit (R. Ellis), no histological sign of MM such as ragged red fibers or negative staining of cytochrome c oxidase was described [3]. Our results are in agreement with those of Harriman: whatever the in vitro contracture test results, pathological findings were heterogenous [4]. Therefore, our observation of mitochondrial abnormalities in 25 of 234 patients (10.6%) led us to investigate these patients further by additional adequate tests.


Malignant Hyperthermia Malignant Hyperthermia Carnitine Palmitoyl Transferase Mitochondrial Myopathy Mitochondrial Defect 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ohtani Y, Milke T, Ishitsu T, Matsuda I, Tamari H (1985) A case of malignant hyperthermia with mitochondrial dysfunction. Brain Dev 7: 249Google Scholar
  2. 2.
    Kozak-Ribbens G, Figarella Branger D, Rodet L, Coulom Pontier F, Confort Gouny S, Bendahan D, Pellissier JF, Desnuelle C, Cozzone PJ (1992) Malignant hyperthermia, heat stroke and mitochondrial myopathies. In: 6th International Workshop, Hershey, PAGoogle Scholar
  3. 3.
    Harriman DGF (1992) The pathology of malignant hyperthermia. In: Mastaglia FL, Lord Walton of Detchant (eds) Skeletal muscle pathology. Churchill, London, pp 541-562Google Scholar
  4. 4.
    Figarella-Branger D, Kozak-Ribbens G, Rodet L, Aubert M, Borsarelli J, Cozzone PJ, Pellissier JF (1993) Pathological findings in 165 patients explored for malignant hyperthermia susceptibility. Neuromusc Disord 5-6: 553 - 556CrossRefGoogle Scholar
  5. 5.
    European MH Group (1984) A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesthesia 56: 1267 - 1269CrossRefGoogle Scholar
  6. 6.
    Gronert GA, Milde JH (1981) Variations in onset of porcine malignant hyperthermia. Anesth Analg 60: 499 - 503PubMedGoogle Scholar
  7. 7.
    Mac Lennan D, Phillips MS (1992) Malignant hyperthermia. Science 256: 789 - 794CrossRefGoogle Scholar
  8. 8.
    Ball SP, Johnson KJ (1993) The genetics of malignant hyperthermia. J Med Genet 30: 89 - 93PubMedCrossRefGoogle Scholar
  9. 9.
    Britt BA, Endenyi L, Eng D, Cadman DL, Man Fan H, Fung HYK (1975). Porcine malignant hyperthermia: effect of halothane on mitochondrial respiration and calcium accumulation. Anesthesiology 42: 292 - 300PubMedCrossRefGoogle Scholar
  10. 10.
    Ruttenbeek W, Verburg MP, Janssen AJM, Stadhouders AM, Sengers RCA (1984) In vivo induced malignant hyperthermia in pigs. II. Metabolism of skeletal muscle mitochondria. Acta Anaesthesiol Scand 28: 9-13CrossRefGoogle Scholar
  11. 11.
    Cheah KS, Cheah AM (1981) Skeletal muscle mitochondria phospholipase A2 and the interaction of mitochondria and sarcoplasmic reticulum in porcine malignant hyperthermia. Biochim Biophys Acta 638: 40 - 49PubMedCrossRefGoogle Scholar
  12. 12.
    Fletcher JE, Rosenberg H, Michaux K, Tripolitis L, Lizzo FH (1989) Triglycerides, not phospholipides, are the source of elevated free fatty acids in muscle from patients susceptible to malignant hyperthermia. Eur J Anaesthesiol 6: 355 - 362PubMedGoogle Scholar
  13. 13.
    Gronert GA, Heffron JJA (1979) Skeletal muscle mitochondria in porcine malignant hyperthermia: respiratory activity, calcium functions, and depression by halothane. Anesth Analg 58: 76 - 81PubMedGoogle Scholar
  14. 14.
    Sengers RCA, Stadhouders AM (1987) Secondary mitochondrial pathology. J Inherited Metab Dis 10 (S1): 98 - 104PubMedCrossRefGoogle Scholar
  15. 15.
    Vladutiu GD, Hogan K, Saponara I, Tassini L, Conroy J (1993) Carnitine palmitoyl transferase deficiency in malignant hyperthermia. Muscle Nerve 16: 485 - 491PubMedCrossRefGoogle Scholar
  16. 16.
    Desnuelle C, Birch Machin M, Pellissier JF, Bindoff LA, Ackrell BAC, Turnbull DM (1989) Multiple defects of the respiratory chain incoding complex II in a family with myopathy and encephalopathy. Biochem Biophys Res Commun 163: 695 - 700PubMedCrossRefGoogle Scholar
  17. 17.
    Bendahan D, Confort Gouny S, Kozak-Ribbens G, PJ Cozzone (1993) Investigation of metabolic myopathies by P31 MRS using a standardized rest-exercise-recovery protocol: a survey of 800 explorations. MAGMA 1: 91 - 104CrossRefGoogle Scholar
  18. 18.
    Bendahan D, Desnuelle C, Vanuxem D, Confort Gouny S, Figarella Branger D, Pellissier JF, Kozak-Ribbens G, Pouget J, Serratrice G, Cozzone PJ (1992) 31P NMR spectroscopy and ergometer exercise test as evidence for muscle oxydative performance improvement with coenzyme Q in mitochondrial myopathies. Neurology 42: 1203 - 1208Google Scholar

Copyright information

© Springer-Verlag Tokyo 1996

Authors and Affiliations

  • Geneviève Kozak-Ribbens
    • 1
  1. 1.Laboratoire Associé à l’Assistance Publique à Marseille, Faculté de MédecineCentre de Résonance Magnétique et Médicale (CRMBM), Centre National de la Recherche Scientifique (CNRS) Unité de Recherche Associée (URA) 1186MarseilleFrance

Personalised recommendations